Les thérapeutiques ciblées ou le traitement des mécanismes moléculaires de la progression tumorale

  • J.-Y. Blay
  • J. Fayette
  • I. Ray-Coquard
Part of the Abord clinique book series (ONCOLPRAT)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Savage DG, Antman KH (2002) Imatinib mesylate—a new oral targeted therapy. N Engl J Med 346: 683–93CrossRefPubMedGoogle Scholar
  2. 2.
    Druker BJ, Talpaz M, Resta DJ et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1084–6Google Scholar
  3. 3.
    Druker BJ, Sawyers CL, Kantarjian H et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038–42PubMedGoogle Scholar
  4. 4.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. (2001) Effect of the tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastro-intestinal stromal tumor. N Eng J Med 344: 1052–6Google Scholar
  5. 5.
    Ray-Coquard I, Le Cesne A, Blay JY (2001) [STI571 and gastro-intestinal stromal tumors]. Bull Cancer 88: 661–2PubMedGoogle Scholar
  6. 6.
    Van Oosterom A, Judson I, Verwej J et al. (2002) Update of the Imatimib (STI 571, Imatinib) phase I in gastro-intestinal stromal tumors. Proc Am Soc Clin Oncol 21 (abstract 327)Google Scholar
  7. 7.
    Van Oosterom A, Judson I, Verwej J et al. (2001) Safety and efficacy of Imatimib (STI-571) in metastatic gastro-intestinal stromal tumors: a phase I study. Lancet 358: 1421–3PubMedGoogle Scholar
  8. 8.
    Demetri GD, von Mehren M, Blanke CD et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastro-intestinal stromal tumors. N Engl J Med 347: 472–80CrossRefPubMedGoogle Scholar
  9. 9.
    Verweij J, van Oosterom AT, Blay JY et al. (2003) Imatinib (Gleevec) an active agent for gastro-intestinal stromal tumors (GIST), but not for other soft tissue sarcoma (STS) subtypes not characterized for KIT and PDGF-R ex-pression, results of EORTC phase II studies. Eur J Cancer 39(14): 2006–11CrossRefPubMedGoogle Scholar
  10. 10.
    Berman J, O’Leary TJ (2001) Gastro-intestinal stromal tumor workshop. Hum Pathol 32: 578–82CrossRefPubMedGoogle Scholar
  11. 11.
    Pidhorecky I, Cheney RT, Kraybill WG (2000) Gastro-intestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 7: 705–12PubMedGoogle Scholar
  12. 12.
    Miettinen M, Sarlomo-Rikala M, Lasota J (1999) Gastro-intestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 30: 1213–20PubMedGoogle Scholar
  13. 13.
    Nishida T, Hirota S (2000) Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 15: 1293–301PubMedGoogle Scholar
  14. 14.
    Longley BJ, Reguera MJ, Ma Y (2001) Classes of c-kit activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 25: 571–6CrossRefPubMedGoogle Scholar
  15. 15.
    Linnekin D (1999) Early signaling pathways activated by c-kit in hematopoietic cells. Int J Bioch Cell Biol 31: 1053–74Google Scholar
  16. 16.
    Huizinga JD, Thuneberg L, Kluppel M et al. (1995) W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373: 347–9PubMedGoogle Scholar
  17. 17.
    Vliagoftis H, Worobec AS, Metcalf DD (1997) The proto-oncogene c-kit and c-kit ligand in human disease. J Alleg Clin Immunol 100: 435–40Google Scholar
  18. 18.
    Andersson J, Sjogren H, Meis-Kindblom et al. (2002) The complexicity of KIT gene mutations and chromosome re-arrangements and their clinical correlation in gastro-intestinal stromal (pacemaker cell) tumors. Amer J of Pathol 160Google Scholar
  19. 19.
    Heinrich MC, Corless CL, Blanke C et al. (2002) KIT mutational status predict clinical response to STI-571 in patients with metastatic gastro-intestinal stromal tumors. Proc. Am Soc Clin Soc 21 (abstract 6)Google Scholar
  20. 20.
    Maeyama H, Hidaka E, Ota H et al. (2001) Familial gastro-intestinal stromal tumor with hyperg-mentation: association with a germline mutation of the c-kit gene. Gastro-enterology 120: 210–5Google Scholar
  21. 21.
    Franquemont DW (1995) Differentiation and risk assessment of gastro-intestinal stromal tumors. Am J Clin Pathol 103: 41–7PubMedGoogle Scholar
  22. 22.
    Cooper PN, Quirque P, Hardy GJ et al. (1992) A flow, cytometric, clinical and histological study of stromal neoplasms of the gastro-intestinal tract. Am J Surg Pathol 16: 163–70PubMedGoogle Scholar
  23. 23.
    Cunnigham RE, Federspiel BH, McCarthy WF et al. (1993) Predicting prognosis of gastrointestinal stromal smooth muscle tumors: Role of clinical and histologic evaluation, flow cyto-metry and image cytometry. Am J Surg Pathol 17: 588–94Google Scholar
  24. 24.
    Taniguchi M, Nishida T, Hirota S et al. (1999) Effect of c-kit mutation on prognosis of gastro-intestinal stromal tumors. Cancer Res 59: 4297–300PubMedGoogle Scholar
  25. 25.
    Lasota J, Jazinski M, Sarlomo-Rikala M et al. (1999) Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastro-intestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154: 53–60PubMedGoogle Scholar
  26. 26.
    Seidal T, Edvardsson H (1999) Expression of c-kit and Ki 67 provides information about the possible cell of origin and clinical course of gastro-intestinal stromal tumours. Histopathology 34: 416–24CrossRefPubMedGoogle Scholar
  27. 27.
    Berman J, O’Leary T (2001) Gastro-intestinal stromal tumors workshop. Human Pathol 32: 578–82Google Scholar
  28. 28.
    Singer S, Rubin BP, Lux ML et al. (2002) Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastro-intestinal stromal tumors. J Clin Oncol 15; 20(18): 3898–905Google Scholar
  29. 29.
    Heinrich MC, Corless CL, Duensing A et al. (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003 Jan 31; 299(5607): 708–10. Epub 2003 Jan 09CrossRefPubMedGoogle Scholar
  30. 30.
    Corless C, Fletcher JA, Heinrich MC (2004) Biology of gastro-intestinal stromal tumors. J Clin Oncol 22: 3813–25CrossRefPubMedGoogle Scholar
  31. 31.
    Verweij J, Casali P, Zalcberg J et al. (2004) Improved progression free survival in gastro-intestinal stromal tumors with high dose Imatinib. Results of a randomized phase III study of the EORTC, ISG and AGITG. Lancet 364: 1127–34CrossRefPubMedGoogle Scholar
  32. 32.
    Blay JY, Bonvalot S, Casali P et al. (2005) Consensus Meeting for the management of Gastro-Intestinal Stromal Tumors. Report of the GIST consensus conference of March 20–21st, 2004 under the auspices of ESMO. Ann Oncol 16(4): 566–78CrossRefPubMedGoogle Scholar
  33. 33.
    Debiec-Rychter M, Dumez H, Judson I et al. (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastro-intestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40: 689–95CrossRefPubMedGoogle Scholar
  34. 34.
    Demetri GD, Desai J, Fletcher JA et al. (2004) SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastro-intestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 23, 195 (abstract 3001)Google Scholar
  35. 35.
    Apperley J, Garembas M, Melo JV et al. (2002) Response to imatinib mesylate in patients with chronic myelomonocytic leukemia with re-arrangements or platelet derived growth factor receptor beta. New Engl J Med 347: 481–7CrossRefPubMedGoogle Scholar
  36. 36.
    Simon MP, Pedeutour F, Sirvent N et al. (1997) Deregulation of the latelet derived growth factor gene via fusion with col1a1 in dermatofibrosarcoma protuberans and giant cell fibroblastoma. Nat Genet 15: 95–8CrossRefPubMedGoogle Scholar
  37. 37.
    Rubin BP, Schuetze SM, Eary JF et al. (2002) Molecular targeting of PDGF B by imatinib mesylate in a patient with metasatic dermatofibro-sarcoma protuberans. J Clin Oncol 20: 3586–91CrossRefPubMedGoogle Scholar
  38. 38.
    Maki RG, Awan RA, Dixon RH et al. (2002) Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100: 623–6CrossRefPubMedGoogle Scholar
  39. 39.
    Pardanani A, Ketterling RP, Brockman SR et al. (2003) CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. BloodGoogle Scholar
  40. 40.
    JS, Fletcher JA, Linette GP, Stec J et al. (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8(4): 307–254PubMedGoogle Scholar
  41. 41.
    Spigel DR, Burstein HJ (2003) Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 4(5): 329–37PubMedGoogle Scholar
  42. 42.
    Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal anti-body against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–92CrossRefPubMedGoogle Scholar
  43. 43.
    Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2: 727–39CrossRefPubMedGoogle Scholar
  44. 44.
    Yang JC, Haworth L, Sherry RM et al. (2003) A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–34CrossRefPubMedGoogle Scholar
  45. 45.
    Negrier S, Perol D, Menetrier-Caux C et al. (2004) Groupe français d’Immunotherapie. Interleukin-6, inter-leukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6—from the Groupe Francais d’Immunotherapie. J Clin Oncol Jun 15; 22(12): 2371–8Google Scholar
  46. 46.
    Hurwitz H, Fehrenbacher L (2004) Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3; 350(23): 2335–42CrossRefPubMedGoogle Scholar
  47. 47.
    Motzer RJ, Rini I, Michaelson MD et al. (2004) SU011248, a novel tyrosine kinase inhibitor shows antitumor activity in second line therapy for patients with metastatic renal cell carcinoma: results of a phase II trial. Proc ASCO 23: 381 (abstract 4500)Google Scholar
  48. 48.
    Ratain MJ, Flaherty KT, Stadler WM et al. (2004) Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial. Proc ASCO 23: 381 (abstract 4501)Google Scholar
  49. 49.
    Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4: 397–406CrossRefPubMedGoogle Scholar
  50. 50.
    Giaccone G (2004) The role of gefitinib in lung cancer treatment. Clin Cancer Res Jun 15; 10(12 Pt 2): 4233s–4237sGoogle Scholar
  51. 51.
    Birnbaum A, Ready N (2005) Gefitinib therapy for non-small cell lung cancer. Curr Treat Options Oncol. 2005 Jan; 6(1): 75–81Google Scholar
  52. 52.
    Perez-Soler R, Chachoua A, Hammond LA et al. (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16): 3238CrossRefPubMedGoogle Scholar
  53. 53.
    Cappuzzo F, Gregorc V, Rossi E et al. (2003) Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21: 2658–63CrossRefPubMedGoogle Scholar
  54. 54.
    Lynch TJ, Bell DW, Sordella R et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 May 20; 350(21): 2129–39CrossRefPubMedGoogle Scholar
  55. 55.
    Paez JG, Janne PA, Lee JC et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 4; 304(5676): 1497–500CrossRefPubMedGoogle Scholar
  56. 56.
    Sordella R, Bell DW, Haber DA et al. (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004 Aug 20; 305(5687): 1163–7CrossRefPubMedGoogle Scholar
  57. 57.
    Pao W, Miller V, Zakowski M et al. (2004) EGF receptor gene mutations are common in lung cancers from “ never smokers ” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004 Sep 7; 101(36): 13306–11CrossRefPubMedGoogle Scholar
  58. 58.
    Stephens P, Hunter C, Bignell G et al. (2004) Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431(7008): 525–6CrossRefPubMedGoogle Scholar
  59. 59.
    Hainsworth JD, Sosman JA, Spigel DR et al. (2004) Phase II trial or bevacizumab and erlotinib in patients ith metastatic renal cell carcinoma. Proc ASCO 23: 381 (abstract 4502)Google Scholar
  60. 60.
    Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). New Engl J Med 351: 337–45CrossRefPubMedGoogle Scholar
  61. 61.
    Robert F, Ezekiel MP, Spencer SA et al. (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19: 3234–43PubMedGoogle Scholar
  62. 62.
    Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14: 520–35PubMedGoogle Scholar
  63. 63.
    Johnson P, Glennie M (2003) The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 30(1 Suppl 2): 3–8PubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • J.-Y. Blay
  • J. Fayette
  • I. Ray-Coquard

There are no affiliations available

Personalised recommendations